Filing Flows › ADC Therapeutics SA (ADCT) › Product revenues, net revenue
ADC Therapeutics SA (ADCT) Product revenues, net revenue by quarter
ADC Therapeutics SA's Product revenues, net revenue was $18.6M in Q2 2026 (second quarter 2026), -7% from Q1 2026. Over the last 6 quarters it ranged from $15.8M (Q3 2025) to $22.3M (Q4 2025).
| Quarter | Product revenues, net revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $18.6M | -7% | +3% |
| Q1 2026 | $20.0M | -10% | +15% |
| Q4 2025 | $22.3M | +42% | — |
| Q3 2025 | $15.8M | -13% | — |
| Q2 2025 | $18.1M | +4% | — |
| Q1 2025 | $17.4M | — | — |
Q2 2026 at a glance
ADC Therapeutics SA, Q2 2026: revenue $19.2M (+2% year over year), operating margin -132.0%, net loss $16.6M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is ADC Therapeutics SA's Product revenues, net revenue?
ADC Therapeutics SA's Product revenues, net revenue was $18.6M in Q2 2026 (second quarter 2026), -7% from Q1 2026.
How has ADC Therapeutics SA's Product revenues, net revenue changed?
Over the last 6 quarters it ranged from $15.8M (Q3 2025) to $22.3M (Q4 2025).